Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14557688 | 0.84 | GABRA1 (0.39) | MAPTPOLBKDM4EGABRA1GABRB2 | |
| SCHEMBL5144552 | 0.84 | HTT (0.39) | MAPTHTTSMN1; SMN2POLBHCAR2 | |
| SCHEMBL8435109 | 0.84 | HTT (0.36) | MAPTHTTSMN1; SMN2POLBHCAR2 | |
| SCHEMBL16213437 | 0.81 | TACR1 (0.36) | MAPTHTTSMN1; SMN2POLBHCAR2 | |
| SCHEMBL26614750 | 0.79 | POLB (0.35) | MAPTHTTSMN1; SMN2POLBHCAR2 | |
| SCHEMBL13534147 | 0.77 | GPR55 (0.35) | MAPTHTTSMN1; SMN2GABRA1GABRB2 | |
| SCHEMBL14983862 | 0.77 | CYP11B1 (0.39) | HCAR2 | |
| SCHEMBL30846835 | 0.76 | NOS1 (0.34) | GABRA1GABRB2 | |
| SCHEMBL27209028 | 0.76 | NOS1 (0.34) | GABRA1GABRB2 | |
| SCHEMBL670394 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4327877-A2 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRad Therapeutics, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20230303494-A1 | BENZYLAMINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | ACADEMY OF MILITARY MEDICAL SCIENCES (CN) | 2023-09-28 | — | — | US | disclosed |
| EP-3743430-B1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11697649-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-07-11 | — | — | US | disclosed |
| EP-4198017-A1 | BENZYLAMINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | Academy of Military Medical Sciences (CN) | 2023-06-21 | — | — | EP | disclosed |
| WO-2022033303-A1 | BENZYLAMINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 中国人民解放军军事科学院军事医学研究院 | 2022-02-17 | — | — | WO | disclosed |
| US-20180222891-A1 | 3-(1H-INDOL-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2018-08-09 | — | — | US | disclosed |
| US-20180221350-A1 | 3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2018-08-09 | — | — | US | disclosed |
| US-20180222923-A1 | 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B] PYRIDINES AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2018-08-09 | — | — | US | disclosed |
| US-20180221353-A1 | 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2018-08-09 | — | — | US | disclosed |
| US-9012472-B2 | 1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2015-04-21 | — | — | US | disclosed |
| US-8987298-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2015-03-24 | — | — | US | disclosed |
| US-20150072981-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2015-03-12 | — | — | US | disclosed |
| US-8883822-B2 | 1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2014-11-11 | — | — | US | disclosed |
| US-20140194441-A1 | 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140179696-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2014-06-26 | — | — | US | disclosed |
| US-8673936-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2014-03-18 | — | — | US | disclosed |
| US-8664241-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2014-03-04 | — | — | US | disclosed |
| US-20130296302-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2013-11-07 | — | — | US | disclosed |
| US-20130267495-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2013-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180222891-A1 | 3-(1H-INDOL-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | MAPT 1433/4885HTT 1260/4885SMN1; SMN2 2011/4885 |
| US-11697649-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | WNT1, WNT3, WNT3A | MAPT 154/4885HTT 835/4885SMN1; SMN2 3885/4885 |
| US-20230303494-A1 | BENZYLAMINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | CD274, PDCD1, PDCD1LG2 | MAPT 2862/4885HTT 3817/4885SMN1; SMN2 3374/4885 |
| US-20140179696-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | MAPT 154/4885HTT 835/4885SMN1; SMN2 3885/4885 |
| US-20130296302-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | COL1A1, NOX4, FGF1 | MAPT 107/4885HTT 1498/4885SMN1; SMN2 654/4885 |
| US-20180221350-A1 | 3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | MAPT 1895/4885HTT 2290/4885SMN1; SMN2 1842/4885 |
| US-20150072981-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | COL1A1, NOX4, FGF1 | MAPT 107/4885HTT 1498/4885SMN1; SMN2 654/4885 |
| US-20140194441-A1 | 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | MAPT 134/4885HTT 827/4885SMN1; SMN2 2618/4885 |
| US-20180222923-A1 | 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B] PYRIDINES AND THERAPEUTIC USES THEREOF | WNT1, WNT3A, WNT3 | MAPT 3198/4885HTT 3142/4885SMN1; SMN2 2475/4885 |
| US-20180221353-A1 | 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | MAPT 3165/4885HTT 3298/4885SMN1; SMN2 2283/4885 |
| US-20130267495-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | MAPT 154/4885HTT 835/4885SMN1; SMN2 3885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.